spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Protagen Protein Services expands analytical Service Spectrum in Biosimilar Development Support

Protagen Protein Services

Faster, more accurate characterization of biomolecular stability using Differential Scanning Calorimetry

Heilbronn/Dortmund February 2019: The success or failure of the development of a biopharmaceutical product is also governed by protein stability. Protein stability is considered a critical parameter during manufacturing, production, formulation, long term storage, efficacy, and delivery to patients.
To meet our customer demands now and in the future, PPS always invests in new analytical technique and recently added a new Differential Scanning Calorimetry (DSC) device.

Now we can offer the DSC analysis requiring five times less sample amount. Furthermore we are able to state the temperature at which denaturation of the protein begins: T onset of melting. This additional information to the melting temperature of the protein domains provides further insights to the overall stability of the analyzed biotherapeutic drug.

The new method extends our capabilities to obtain additional complementary results, for demonstrating Biosimilarity and Batch-to-Batch Comparability for the benefit of our customers. As additional value it offers developers a quick stability assay to identify biotherapeutics with good stability potential and enables to determine the conditions that maximize the shelf-life of a biotherapeutic.

As we help to develop highly stable protein therapeutics the production of drugs will become more cost-effectively, may face fewer challenges during the manufacturing process, and they are more likely to remain functional during formulation and storage without any aggregation or alteration.

Besides the new DSC method it is outmost important to also analyze the protein research object with other stability indicating methods. Learn more from our broad analytical spectrum at www.protagenproteinservices.com.

Key words: Biosimilars/protein analysis/drug development/analytical service

About Protagen Protein Services GmbH (PPS):

Protagen Protein Services (PPS) is a world leading CRO and recognized expert in mass spectrometry methods for analytical services in protein science. Over 20 years of market experience and the comprehensive spectrum of validated analytical methods ensure the highest quality for customers in the pharmaceutical, biotech and life science industry. PPS supports Biosimilar developers with a broad range of analytical methods and consulting in achieving and demonstrating Biosimilarity. For developing new biological entities (NBEs) PPS supports customer approaches by all-in-one-hand service with including full analytical support, complete documentation and outstanding project management to gain market success.

Contact:

Tobias Timtner
Marketing Manager
Protagen Protein Services GmbH 
Inselwiesenstraße 10
74076 Heilbronn, Germany

Tel.: +49 7131 74504-0
Fax: +49 7131 74 504-299
phone +49 231 9742 61 00
email contact@protagenproteinservices.com
web www.protagenproteinservices.com
email Protagen Protein Services (GmbH), Inselwiesenstraße 10, D-74076 Heilbronn
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Protagen Protein Services expands analytical Service Spectrum in Biosimilar Development Support

Heilbronn/Dortmund February 2019: The success or failure of the development of a biopharmaceutical product is also governed by protein stability. Protein stability is considered a critical parameter during manufacturing, production, formulation, long term storage, efficacy, and delivery to patients. To meet our customer demands now and in the future, PPS always invests in new analytical technique and recently added a new Differential Scanning Calorimetry (DSC) device.
More info >>


White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

Industry Events

INTERPHEX 2019

2-4 April 2019, Javits Center, New York

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA). Dedicated to Innovation, Technologies and Knowledge, the show focuses on the entire product development life cycle.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement